William J. Meury serves as Chief Executive Officer of Incyte Corporation, a biopharmaceutical company dedicated to advancing innovative therapies in oncology, immunology, and inflammation. With more than 25 years of experience in the pharmaceutical industry, Meury joined Incyte in February 2014 as Executive Vice President and Chief Commercial Officer. Prior to Incyte, he spent over two decades at Novartis, where he rose to President of Novartis Oncology for the United States, overseeing the commercialization of key oncology products and driving significant market growth in cancer therapies. Under Meury's leadership, Incyte has achieved remarkable commercial success, including the expansion of its flagship product Jakafi (ruxolitinib) into new indications, the U.S. launch of Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo, and the approval of Monjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma. Promoted to President in 2019 and CEO in September 2021, succeeding Heman Chao, Meury has propelled the company's annual revenue beyond $4 billion, strengthened its pipeline of precision medicines, and fostered strategic partnerships to accelerate drug development. As CEO, Meury continues to guide Incyte's vision for transforming patient outcomes through targeted therapies and a robust global presence. His proven track record in commercial strategy, operational excellence, and innovation has solidified Incyte's position as a leader in biotechnology, with a focus on sustainable growth and expanding access to life-changing treatments.